Nuveen Asset Management, LLC - AIMMUNE THERAPEUTICS INC ownership

AIMMUNE THERAPEUTICS INC's ticker is AIMT and the CUSIP is 00900T107. A total of 129 filers reported holding AIMMUNE THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is 0.77 and the average weighting 0.9%.

Quarter-by-quarter ownership
Nuveen Asset Management, LLC ownership history of AIMMUNE THERAPEUTICS INC
ValueSharesWeighting
Q3 2020$2,250,000
-29.3%
178,595
-6.2%
0.00%0.0%
Q2 2020$3,182,000
+17.0%
190,418
+1.0%
0.00%0.0%
Q1 2020$2,719,000
-56.3%
188,577
+1.5%
0.00%
-50.0%
Q4 2019$6,217,000
+55.8%
185,753
-2.5%
0.00%0.0%
Q3 2019$3,991,000
+0.6%
190,600
-0.0%
0.00%0.0%
Q2 2019$3,969,000190,6550.00%
Other shareholders
AIMMUNE THERAPEUTICS INC shareholders Q2 2019
NameSharesValueWeighting ↓
Aisling Capital LLC 1,240,000$25,966,00057.34%
Foresite Capital Management II, LLC 2,605,499$54,559,00011.53%
Foresite Capital Management III, LLC 611,893$12,813,0004.89%
Palo Alto Investors LP 3,471,740$72,698,0004.84%
SANDERS MORRIS HARRIS LLC 486,906$10,196,0002.47%
Eventide Asset Management 3,084,000$64,579,0002.13%
Sofinnova Investments, Inc. 346,770$7,261,0000.66%
EMERALD ADVISERS, LLC 610,511$12,784,0000.60%
RICE HALL JAMES & ASSOCIATES, LLC 752,358$15,754,0000.56%
EMERALD MUTUAL FUND ADVISERS TRUST 587,464$12,301,0000.54%
View complete list of AIMMUNE THERAPEUTICS INC shareholders